5,718 Shares in Medpace Holdings, Inc. $MEDP Purchased by Entropy Technologies LP

Entropy Technologies LP purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 5,718 shares of the company’s stock, valued at approximately $3,212,000.

Several other large investors have also recently added to or reduced their stakes in the company. BOKF NA raised its holdings in Medpace by 0.8% during the third quarter. BOKF NA now owns 2,542 shares of the company’s stock worth $1,307,000 after purchasing an additional 20 shares in the last quarter. Valeo Financial Advisors LLC raised its holdings in Medpace by 5.0% during the fourth quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock worth $249,000 after purchasing an additional 21 shares in the last quarter. UMB Bank n.a. raised its holdings in Medpace by 5.6% during the fourth quarter. UMB Bank n.a. now owns 450 shares of the company’s stock worth $253,000 after purchasing an additional 24 shares in the last quarter. Schulhoff & Co. Inc. increased its holdings in Medpace by 1.1% in the fourth quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock valued at $1,237,000 after buying an additional 25 shares in the last quarter. Finally, Kaufman Rossin Wealth LLC increased its holdings in Medpace by 3.4% in the fourth quarter. Kaufman Rossin Wealth LLC now owns 795 shares of the company’s stock valued at $447,000 after buying an additional 26 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

MEDP has been the subject of a number of research analyst reports. BMO Capital Markets dropped their target price on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a report on Friday, April 24th. Royal Bank Of Canada dropped their target price on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a report on Friday, April 24th. Barclays dropped their target price on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a report on Friday, April 24th. Weiss Ratings cut shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, April 6th. Finally, TD Cowen raised shares of Medpace from a “sell” rating to a “hold” rating and dropped their target price for the company from $462.00 to $419.00 in a report on Wednesday, February 18th. Four research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $467.08.

Insider Activity at Medpace

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the sale, the general counsel directly owned 20,343 shares in the company, valued at $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, President Jesse J. Geiger sold 31,707 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the sale, the president owned 15,000 shares in the company, valued at $6,829,500. This represents a 67.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 20.50% of the stock is owned by corporate insiders.

Medpace Stock Performance

Shares of Medpace stock opened at $467.34 on Monday. The company has a 50-day moving average of $456.43 and a two-hundred day moving average of $503.84. The stock has a market cap of $13.35 billion, a PE ratio of 29.37, a price-to-earnings-growth ratio of 2.37 and a beta of 1.18. Medpace Holdings, Inc. has a 12-month low of $294.07 and a 12-month high of $628.92.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, beating the consensus estimate of $3.74 by $0.54. The business had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The company’s quarterly revenue was up 26.5% on a year-over-year basis. During the same period in the prior year, the business earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, sell-side analysts forecast that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.